NC-SYNTERACT
4.2.2020 13:02:08 CET | Business Wire | Press release
Synteract , an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint into Asia Pacific and Africa, and offers another core biometrics services hub, complementary to those it operates in Europe and the U.S.
Clindata , with offices in Bloemfontein, South Africa, and Colombo, Sri Lanka, is a biometrics Clinical Research Organization, offering biostatistics, programming and data management services across all phases of drug development. Clindata’s Veterinary division will continue to operate under the Clindata name, independently from Synteract, while the Human Health Biometrics division will combine with Synteract. The combination of Clindata’s experienced team of biometrics professionals with that of Synteract’s further enhances Synteract’s biometrics capabilities as part of its integrated, full-service program; dedicated FSP solution , or as a standalone biometrics service to augment clients’ in-house capabilities.
“Like Synteract, Clindata is known for high quality service delivery, collaboration, agility and expertise of its teams,” says Synteract CEO Steve Powell . “Innovative changes in biometrics are transforming the ways in which clinical study data is collected, integrated and analyzed. Rich patient data gives researchers insights into disease progression and response to therapy in ways we have not seen before. This is an exciting time to be adding even more expertise to our teams and will allow us to deliver global biometrics services covering every time-zone.”
With a wealth of data management, CDISC, biostatistics and SAS experience, the Clindata team have significant experience running Phase I-IV studies across the complementary therapeutic areas of Synteract. Clindata CEO, Theo Erasmus, adds, “With our combined biometrics capabilities, clients will benefit from a complete service offering incorporating all data components from research, advice on study design, document planning to PK analyses and results interpretation, as well as global capabilities, all provided by one integrated CRO. We are glad to be joining Synteract and creating a world class delivery team.”
Synteract is a portfolio company of Amulet Capital Partners, LP. Financial terms are not being disclosed.
About Synteract
“Bringing Clinical Trials to Life ” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development with multi-disciplinary teams and deep expertise. Synteract has conducted nearly 4,000 studies on six continents and has contributed to more than 240 product approvals. Synteract offers notable depth of expertise in oncology, dermatology, general medicine, neuroscience, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter .
About Clindata
Founded in 2012, Clindata is a Contract Research Organization (CRO) based in South Africa. The Clindata core team of experienced, dedicated staff has worked for in the CRO and health industry for many years. We bring a wealth of Data Management, CDISC, Biostatistics and SAS experience. Our team members have significant experience gained from working on studies of various phases and throughout an array of therapeutic areas.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eaton Strengthens European Manufacturing With Expanded Production Facility in Austria1.10.2026 09:00:00 CEST | Press release
Increased capacity supports growing demand from electrification and critical infrastructure marketsNew fully automated miniature circuit breaker production and expanded low-voltage systems assembly capacity in Schrems5,000 m² facility expansion combines advanced automation, digital integration and end-to-end product traceability Eaton will celebrate the expansion of its manufacturing facility in Schrems, Austria, on 1 October 2026. The expansion supports growing demand driven by electrification and digitalisation across Europe while increasing regional manufacturing capacity for electrical protection and power management solutions. Completed in less than ten months, the expansion combines fully automated production with advanced digital integration and end-to-end product traceability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001416101/en/ Eaton expanded manufacturing capacity in Europe for power management solutions
Aegir Insights Launches Next-Generation Energy Intelligence Platform1.10.2026 09:00:00 CEST | Press release
One platform across wind, solar, storage and data centers combining commercial intelligence with investment modeling; the foundation for energy vertical AI Aegir Insights today announced the launch of its next-generation energy intelligence platform, combining commercial data, expert research and investment modeling in a single environment for investment decisions across onshore wind, offshore wind, solar, energy storage and data centers. The Aegir Platform links the intelligence that informs commercial decisions in renewables: Markets, companies, projects, auctions, supply chains and transactions. Together with analyst research and investment software, it gives the full context to assess where to invest, which assets and counterparties to consider, and what determines their viability. "Energy investment depends on understanding how projects, companies and markets fit together," said Scott Urquhart, CEO of Aegir Insights. "An asset's ownership, auction position, supply chain and route
Advanced MRI Imaging Reveals Changes in Muscle Composition and Fat Infiltration During Obesity Treatment1.10.2026 08:55:00 CEST | Press release
AMRA Chief Scientific Officer Dr. Jennifer Linge will present at EASD 2026, highlighting how quantitative MRI can reveal changes in muscle that conventional measures does not fully capture. As obesity treatment continues to evolve, understanding what happens to muscle during weight loss is becoming increasingly important. At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD),AMRA Medical Chief Scientific Officer Dr. Jennifer Linge will present how advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930545312/en/ Advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment The presentation addresses an increasingly important question in obesity research: what happens to muscle as people lose weight?Understanding muscle
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution1.10.2026 08:30:00 CEST | Press release
Reorganization of Plenitude’s capital structure expands Ares’ economic and governance participation in the company Ares Management Corporation (NYSE: ARES), a leading global investment manager, announced today that Ares Alternative Credit funds (“Ares”) participated in a reorganization of the shareholding and governance structure of Plenitude through which Ares and Eni S.p.A (“Eni”) upsized their capital contribution by approximately €1.5 billion, of which over €1 billion is attributable to Ares, based on a pre-money equity valuation of Plenitude of €10.75 billion. Following completion of the transaction, Ares holds 26.24% of Plenitude’s share capital, with Eni holding 65.03% and Energy Infrastructure Partners (“EIP”) as an 8.73% shareholder. Ares first invested in Plenitude in 2025, acquiring a 20% stake in the business for approximately €2 billion. This transaction is geared towards strengthening Plenitude’s capital structure and introduces an enhanced governance framework that suppo
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics1.10.2026 08:10:00 CEST | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930257993/en/ Orifarm Headquarter, Odense Denmark “As European healthcare systems face rising demand, budget pressures, and supply challenges, Orifarm is uniquely positioned to improve access to affordable medicines and strengthen European supply. Our Fit to Scale strategy is about playing an even bigger role in meeting these needs and taking Orifarm to the next level,” says Mads Fink Eriksen,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom